Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009.

OBJECTIVES: To present a revision on the signet-ring cell bladder adenocarcinomas found in our department. METHODS/RESULTS: We reviewed all the transurethral resections of the bladder (TURB) performed between 1990 and 2009 finding 9 cases of primary signet ring cell adenocarcinomas (4 pure and 5 mixed). Eight were male and one female, with ages between 39 and 82 years. Definitive treatment was radical cystectomy with Bricker's urinary diversion in four patients, cysctectomy with Mainz's II diversion in one patient and palliative management with TURB in three cases and percutaneous nephrostomy in the remaining case. We used adyuvant chemotherapy in three cases. Only two patients were alive at the time of the study. Mean survival was 327 days for pure tumors and 586 for the mixed ones. CONCLUSIONS: Signet-ring cell primary adenocarcinoma of the bladder is an uncommon type of tumor, with worse prognosis than transitional cell cancer. It is important to discard other possible metastatic origins(like stomach, prostate, lung, or ovary) because the management will be different. Radical cystectomy is the treatment of choice, with adyuvant chemotherapy if possible. Five year survival is less than 11%

Adenocarcinoma vesical de células en anillo de sello: revisión de nuestros casos entre 1990-2009 / Signet-ring cell adenocarcinoma of the bladder: case review between 1990-2009

OBJETIVOS: Presentar una revisión de los adenocarcinomas primarios de vejiga de células en anillo de sello de nuestro servicio. MÉTODO/RESULTADO: Revisamos las RTU de vejiga realizadas entre 1990 y 2009 encontrando 9 casos de tumores primarios de vejiga de células en anillo de sello (4 puros y 5 mixtos).8 eran varones y 1 mujer, con edades comprendidas entre los 39 y los 82 años. Tratamiento definitivo consistió en cistectomía radical con derivación tipo Bricker en cuatro de los pacientes, cistectomía con derivación Mainz II en otro de ellos y paliativo en los cuatro restantes con RTU en tres casos y NPC paliativas en otro. Empleamos quimioterapia adyuvante en 3 casos. Sólo dos de los pacientes estaban vivos en el momento del estudio. La media de supervivencia fue de 327 días para los tumores puros y de 586 para los mixtos.CONCLUSIÓN: Los adenocarcinomas primarios de vejiga con células en anillo de sello son unos tumores poco frecuentes, con peor pronóstico que los de células transicionales. Es importante que descartemos los posibles orígenes metastásicos (de estómago, próstata, ovario, pulmón) ya que el manejo a seguir será distinto en función de la localización del tumor primario. El tratamiento de elección en los primarios de vejiga es la cistectomía radical, con quimioterapia adyuvante en los casos que sea posible. La supervivencia a 5 años es < al 11%(AU)

OBJECTIVES: To present a revision on the signet-ring cell bladder adenocarcinomas found in our department.METHODS/RESULTS: We reviewed all the transurethral resections of the bladder (TURB) performed between 1990 and 2009 finding 9 cases of primary signet ring cell adenocarcinomas ( 4 pure and 5 mixed). Eight were male and one female, with ages between 39 and 82 years. Definitive treatment was radical cystectomy with Bricker´s urinary diversion in four patients, cysctectomy with Mainz´s II diversion in one patient and palliative management with TURB in three cases and percutaneous nephrostomy in the remaining case. We used adyuvant chemotherapy in three cases. Only two patients were alive at the time of the study. Mean survival was 327 days for pure tumors and 586 for the mixed ones.CONCLUSIONS: Signet-ring cell primary adenocarcinoma of the bladder is an uncommon type of tumor, with worse prognosis than transitional cell cancer. It is important to discard other possible metastatic origins (like stomach, prostate, lung, or ovary) because the management will be different. Radical cystectomy is the treatment of choice, with adyuvant chemotherapy if possible. Five year survival is less than 11%(AU)

Giant cystic degeneration of the rete testis.

OBJECTIVES: We present a case of giant cyst of the rete-testis. METHODS/RESULTS: 85 year-old patient on follow -up for prostate cancer with maximum androgen blockade (MAB) treatment consults for a left hemiscrotum increase in size over a 2-month period. We performed bilateral orchiectomy confirming the histopathological diagnosis of cystic dilatation of the rete-testis sized 11 x 11 x 9 cm. CONCLUSIONS: This case of cystic degeneration of the rete-testis, with a size out of common (11 x 11 x 9 cm versus medium size in the literature: 3 x 3 x 3 cm), could be related with an androgen-estrogen misbalance caused by a MAB in a prostate cancer context.

Degeneración quística gigante de la rete testis / Giant cystic degeneration of the rete testis

OBJETIVOS: Presentar el caso de un quiste gigante de la rete testis.MÉTODO/RESULTADO: Se trata de un paciente de 85 años que durante el seguimiento por un adenocarcinoma de próstata con bloqueo androgénico completo consulta por aumento del tamaño del hemiescroto izquierdo de dos meses de evolución. Se realizó una orquiectomía bilateral, confirmando en el estudio histopatológico de dilatación quística de la rete testis de 11x11x9cm de tamaño. CONCLUSIÓN: Este caso de degeneración quística de la rete testis, con un tamaño fuera de lo común (11x11x9cm, mientras que en la literatura refieren un tamaño medio de 3x3x3cm) podría estar relacionado con el disbalance andrógeno-estrogénico por el BAC en el contexto de un cáncer de próstata(AU)

OBJECTIVES: We present a case of giant cyst of the rete-testisMETHODS/RESULTS: 85 year-old patient on follow-up for prostate cancer with maximum androgen blockade (MAB) treatment consults for a left hemiscrotum increase in size over a 2-month period. We performed bilateral orchiectomy confirming the histopathological diagnosis of cystic dilatation of the rete-testis sized 11x11x9cm.CONCLUSIONS: This case of cystic degeneration of the rete-testis, with a size out of common (11x11x9cm versus medium size in the literature: 3x3x3cm), could be related with an androgen-estrogen misbalance caused by a MAB in a prostate cancer context(AU)